Investigation of the efficacy and safety of eltrombopag to correct thrombocytopenia in moderate to severe dengue patients - a phase II randomized controlled clinical trial

BACKGROUND: The dengue-infected patients with or without hemorrhagic manifestations, typically exhibit moderate to severe thrombocytopenia. A thrombopoietin receptor agonist – eltrombopag has been efficacious in correcting thrombocytopenia in patients with various pathological conditions including i...

Descripción completa

Detalles Bibliográficos
Autores principales: Chakraborty, Sajib, Alam, Saruar, Sayem, Mohammad, Sanyal, Mousumi, Das, Tonmoy, Saha, Piyal, Byapari, Bartholomia Keya, Tabassum, Chowdhury Tamanna, Kabir, Ahmedul, Amin, Md.Robed, Nabi, A.H.M. Nurun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691733/
https://www.ncbi.nlm.nih.gov/pubmed/33294822
http://dx.doi.org/10.1016/j.eclinm.2020.100624

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7691733/
https://www.ncbi.nlm.nih.gov/pubmed/33294822
http://dx.doi.org/10.1016/j.eclinm.2020.100624

Ejemplares similares